← Back to patent-cliff list
Lafutidine
Tier C — Watch / tradeLafutidine
UCB Pharma
Originator
2000
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HRH2
Brand：Protecadin, Stogar, Protecadin OD
Indications (approved)：Duodenal ulcer, Gastric ulcer, Gastro-oesophageal reflux disease, Peptic ulcer
Regional status
US
-
EU
-
China
Approved
2006-05-12
Japan
Approved
2000-01-08
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lafutidine?
Approved indications include: Duodenal ulcer, Gastric ulcer, Gastro-oesophageal reflux disease, Peptic ulcer.
When does the Lafutidine patent expire?
No public expiry year is available for Lafutidine yet; this page updates once verified.
How do I get a quote for Lafutidine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27